EN DE
Watch Sinohealth Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sinohealth Holdings Ltd (2361) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Sinohealth Holdings Ltd stock HK$3.12, price HK$2.85, upside +9.5%, quality 59 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

SH Sinohealth Holdings Ltd logo Thin data Nov 14, 2026

Sinohealth Holdings Ltd

2361 · HK

Solid company and rising price, but the stock is already about fairly priced: meets 2 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Healthy Growth (revenue 5y +15.7 %/yr in CNY) 
Solidly profitable · 16.5% net margin (TTM) 
Generates free cash flow 
2.2% dividend yield · Well covered
Ranks above peers (13/14) 
Fair value HK$3.12 · Fairly valued 
Quality 59/100 
Moderate moat 55/100 · thin data
Dilution deducted on Nov 12: HK$3.68 → HK$3.12 
Thin data 
⚠ Dilution⚠ Thinly traded⚠ Small free float
Watch Sinohealth Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$6.33 HK$1.94 Fair Value HK$3.12 Jul 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

52‑month range HK$1.94 – HK$6.33 · fair‑value band HK$2.08 – HK$4.44 · the HK$2.85 price screens below the HK$3.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Sinohealth Holdings in your weekly email

Every Wednesday you see whether Sinohealth Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sinohealth Technology Holdings Limited provides healthcare solutions for sales and marketing needs of medical product manufacturer clients in Mainland China and internationally.

Show moreShow less

It engages in the research and development, and provision of data insight solutions, data-driven publications and events, and software as a service (SaaS) products; research and development, and operation of Smart Medical Cloud under the business line of SaaS products; management of marketing and promotion services of medicine; operation of SaaS products; provision of internet information and internet data center services; production and publication of videos; and foreign-related market research business.

The company also offers precision marketing solutions; and consulting and marketing services. It serves various fields, such as pharmaceutical industry, retail pharmacies, and physical examination and hospitals.

Sinohealth Technology Holdings Limited was formerly known as Sinohealth Holdings Limited and changes its name to Sinohealth Technology Holdings Limited in February 2026. The company was founded in 2007 and is headquartered in Guangzhou, China.

Stock analysis

Sinohealth Holdings Ltd (2361) currently trades at HK$2.85, while our model-based Fair Value estimate is HK$3.12, so the stock looks roughly fairly valued today (gap 8.7%).

Show more

Valuation

Bull case: the Multiples group reads highest at a median of HK$5.05 per share, and 17 of the 26 models we run sit above the HK$2.85 price.

Bear case: the Asset-Based group reads lowest at HK$1.71, and 9 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$2.08 (bear) to HK$4.44 (bull), the price of HK$2.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Sinohealth Holdings Ltd reported revenue of 419M CNY in FY2025 versus 324M CNY in FY2021, a compound +6.6%/yr. Reported net income was 93.4M CNY in FY2025, compounding +4.3%/yr from FY2021.

Key figures

Market cap HK$1.3B (≈ $164M) Micro · P/E ratio 22.0 · P/S ratio 4.90 · Dividend yield 2.2% · Net margin 22.3% · Return on equity 10.4% · Return on assets (EBIT) 13.3% (5-year average) · Operating margin 5.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).

What moves the price

The share trades about 48% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 10%, 2361 screens cheaper than that median.

Fair Value models

Bear HK$2.08 Fair Value HK$3.12 Bull HK$4.44
Price HK$2.85 · Upside +9.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$2.03 HK$2.64 HK$3.44 80
Growth DCF HK$2.01 HK$2.57 HK$3.25 77
Residual Income HK$1.63 HK$1.79 HK$2.10 76
All 26 models by family
DCF Models
FCF DCF HK$2.03 HK$2.64 HK$3.44 80
Owner Earnings HK$2.14 HK$2.80 HK$3.66 75
5Y Revenue Exit HK$2.45 HK$3.67 HK$5.27 70
5Y EBITDA Exit HK$2.79 HK$4.33 HK$6.18 72
5Y P/E Exit HK$3.22 HK$5.16 HK$7.28 68
10Y Revenue Exit HK$2.18 HK$3.13 HK$4.46 64
10Y EBITDA Exit HK$2.41 HK$3.51 HK$5.05 66
10Y P/E Exit HK$2.64 HK$4.00 HK$5.77 61
Earnings-Based
Graham-Dodd HK$1.65 HK$6.11 HK$8.25 64
Lynch FV HK$2.17 HK$3.11 HK$4.04 61
PEG = 1.0 HK$2.17 HK$3.11 HK$4.04 57
EPV HK$2.09 HK$2.25 HK$2.39 68
Dividend Discount
Gordon GGM HK$1.61 HK$2.61 HK$3.31 69
DDM Multi-Stage HK$1.61 HK$2.51 HK$2.81 67
Multiples
P/E Multiple HK$4.01 HK$5.35 HK$6.68 63
P/S Multiple HK$2.86 HK$3.81 HK$4.77 58
P/B Multiple HK$6.50 HK$8.67 HK$10.84 55
EV/EBIT HK$4.14 HK$5.31 HK$6.49 63
EV/EBITDA HK$3.75 HK$4.79 HK$5.84 64
EV/Revenue HK$2.90 HK$3.88 HK$4.86 52
Asset-Based
NCAV (Graham) HK$1.13 HK$1.71 HK$2.13 52
Growth DCF
Growth DCF HK$2.01 HK$2.57 HK$3.25 77
Rev-Margin DCF HK$2.45 HK$3.65 HK$5.11 70
Economic Profit
Residual Income HK$1.63 HK$1.79 HK$2.10 76
ROIC Compounder HK$2.11 HK$2.38 HK$2.69 70
Growth Earnings
Growth-Adj P/E HK$2.81 HK$4.01 HK$5.21 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 58
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 62
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 57
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 27
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+10.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.7%
Dividend (yield on the price)2.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.38% → 25%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +1.1% a year for the price.

Watch 2361, get fair value alerts →

Compare Sinohealth Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 142 stocks

Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside +9.5% · Above median
Profitability
Return on equity (12 months) 10.4% · Above median
Return on assets 10.8% · Top 25%
Net margin (12 months) 16.5% · Top 25%
Operating margin (12 months) 5.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 9.2% · Above median
Dividend yield (12 months) 2.2% · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 22.0× · Cheaper than median
P/B 1.45× · Cheaper than median
P/S (12 months) 2.53× · Cheaper than median
Price / free cash flow (fiscal year) 16.5× · Cheaper than median
EV/EBITDA 9.9× · Cheaper than median
PEG 4.21× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)46 · sector 16
FUTURE (revenue growth)46 · sector 43
PAST (return on equity)42 · sector 3
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)45 · sector 44

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $301.53 $332.66 +10% vs 2361
Doximity, Inc DOCS $33.34 $36.67 +10% vs 2361
HealthEquity, Inc HQY $103.46 $113.36 +10% vs 2361
Waystar Holding WAY $27.99 $29.10 +4% vs 2361
Tempus AI, Inc TEM $71.60 $52.58 −27% vs 2361
HeartFlow, Inc HTFL $48.46 $30.56 −37% vs 2361
Hinge Health, Inc HNGE $115.39 $51.25 −56% vs 2361
Pro Medicus Limited PME A$201.66 A$85.12 −58% vs 2361
BrightSpring Health Services, Inc BTSG $71.21 $25.72 −64% vs 2361
XtalPi Holdings 2228 HK$5.87 HK$1.53 −74% vs 2361

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sinohealth Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sinohealth Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2361

Frequently asked questions

Is Sinohealth Holdings Ltd (2361) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$3.12 versus a price of HK$2.85, about +10% upside (fairly valued).
What is the fair value of 2361?
Our model-based fair value for Sinohealth Holdings Ltd is HK$3.12 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$2.85.
What is the quality score of 2361?
Sinohealth Holdings Ltd has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinohealth Holdings Ltd (2361)?
Our model-based price target is the fair value of HK$3.12 (as of Nov 14, 2026) from 26 valuation models. Cautious scenario HK$2.08, optimistic scenario HK$4.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinohealth Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$3.12, about +10% upside versus a price of HK$2.85 (fairly valued). Cautious scenario HK$2.08, optimistic scenario HK$4.44. The calculation is refreshed regularly with new filings.
What is the revenue of Sinohealth Holdings Ltd (2361)?
Sinohealth Holdings Ltd reported trailing-twelve-month revenue of about 433M CNY (latest available figure, as of Nov 14, 2026).
Does Sinohealth Holdings Ltd pay a dividend?
Sinohealth Holdings Ltd currently shows a dividend yield of 2.25% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Sinohealth Holdings Ltd (2361) and when is the ex-dividend date?
Sinohealth Holdings Ltd pays a dividend of HK$0.064 per share a year, a dividend yield of 2.2%. The last ex-dividend date was Jun 23, 2026. The payout ratio is 53.5% of earnings. Free cash flow covers the dividend 1.33 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Sinohealth Holdings Ltd (2361)?
For today's price to be fair in a discounted-cash-flow model, Sinohealth Holdings Ltd would have to grow free cash flow by 2.8 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 15.7 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 2361 use?
Our models discount Sinohealth Holdings Ltd at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sinohealth Holdings Ltd that is +2.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Sinohealth Holdings Ltd (2361) delivered so far?
Over the past 5 years revenue at Sinohealth Holdings Ltd grew 15.7 % a year. The price currently implies free-cash-flow growth of +2.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sinohealth Holdings Ltd (2361) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Sinohealth Holdings Ltd (+2.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sinohealth Holdings Ltd (2361)?
The free-cash-flow yield on the price is 6.07 %: that much free cash flow Sinohealth Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sinohealth Holdings Ltd (2361)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinohealth Holdings Ltd it is HK$3.12 per share (as of Nov 14, 2026), against a price of HK$2.85. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Sinohealth Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 2361 trades below its calculated fair value: price HK$2.85, fair value HK$3.12, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2361?
No. The price is what the market pays today (HK$2.85); the fair value is what the company's own numbers justify (HK$3.12). For Sinohealth Holdings Ltd the two are HK$0.2695 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinohealth Holdings Ltd worth?
The market values Sinohealth Holdings Ltd at about HK$1.3B (market capitalisation, as of Nov 14, 2026). Per share that is HK$2.85; our models calculate a fair value of HK$3.12 per share.
What do the bullish and bearish scenarios say about 2361?
Our models span a range for Sinohealth Holdings Ltd: cautious scenario HK$2.08, base HK$3.12, optimistic HK$4.44 per share (as of Nov 14, 2026, price HK$2.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2361?
Sinohealth Holdings Ltd trades at a price-to-earnings ratio of 22.0 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$3.12 is built from several models across several years. Other multiples: PEG 4.2, P/B 1.5, P/S 2.5, EV/EBITDA 9.9.
What is the PEG ratio of 2361?
The PEG ratio of Sinohealth Holdings Ltd is 4.21 (P/E divided by earnings growth, as of Nov 14, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sinohealth Holdings Ltd (2361)?
Balance-sheet figures for Sinohealth Holdings Ltd (as of Nov 14, 2026): return on equity 10.4%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 2361 from its 52-week high?
Sinohealth Holdings Ltd trades at HK$2.85, about 48% below its 52-week high of HK$5.51 and 6% above the low of HK$2.70 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.12 is for.
Which stocks are comparable to Sinohealth Holdings Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinohealth Holdings Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price HK$2.85, calculated fair value HK$3.12 (+10%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2361 calculated?
We run Sinohealth Holdings Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$3.12 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Sinohealth Holdings Ltd currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinohealth Holdings Ltd (2361)?
The closing price on Nov 13, 2026 was HK$2.85. Our model-based fair value is HK$3.12, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinohealth Holdings Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$2.08 to HK$4.44) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sinohealth Holdings Ltd

How large is the market capitalisation of Sinohealth Holdings Ltd (2361)?
The market capitalisation of Sinohealth Holdings Ltd is HK$1.3B (≈ $164M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinohealth Holdings Ltd (2361)?
The price-to-sales ratio of Sinohealth Holdings Ltd is 4.90 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Sinohealth Holdings Ltd (2361)?
The dividend yield of Sinohealth Holdings Ltd is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sinohealth Holdings Ltd (2361)?
The net margin of Sinohealth Holdings Ltd is 22.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sinohealth Holdings Ltd (2361)?
The return on equity (ROE) of Sinohealth Holdings Ltd is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sinohealth Holdings Ltd (2361)?
On an EBIT basis the return on assets of Sinohealth Holdings Ltd is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinohealth Holdings Ltd (2361)?
The operating margin of Sinohealth Holdings Ltd is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinohealth Holdings Ltd (2361)?
Revenue at Sinohealth Holdings Ltd is growing 9.2% versus a year earlier (3y avg +5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sinohealth Holdings Ltd (2361)?
Earnings per share at Sinohealth Holdings Ltd are down 83.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Sinohealth Holdings Ltd in the live analysis

One click puts Sinohealth Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.